Howard Capital Management Inc. Purchases 11,445 Shares of Pfizer Inc. $PFE

Howard Capital Management Inc. grew its position in Pfizer Inc. (NYSE:PFE) by 8.4% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 148,309 shares of the biopharmaceutical company’s stock after acquiring an additional 11,445 shares during the period. Howard Capital Management Inc.’s holdings in Pfizer were worth $3,595,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Capital Advisory Group Advisory Services LLC grew its stake in Pfizer by 2.9% in the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 388 shares during the period. Citizens National Bank Trust Department grew its position in shares of Pfizer by 0.9% in the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock valued at $1,118,000 after purchasing an additional 395 shares during the period. Trust Co of the South grew its position in shares of Pfizer by 1.5% in the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock valued at $712,000 after purchasing an additional 441 shares during the period. Charter Oak Capital Management LLC increased its stake in Pfizer by 4.3% during the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 444 shares in the last quarter. Finally, Ballentine Partners LLC raised its holdings in Pfizer by 0.5% during the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock worth $2,260,000 after buying an additional 458 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on PFE shares. Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Morgan Stanley reduced their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. UBS Group restated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Finally, Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $28.13.

Pfizer Trading Down 0.0%

Pfizer stock opened at $24.76 on Tuesday. The company has a market cap of $140.75 billion, a price-to-earnings ratio of 13.17, a P/E/G ratio of 0.82 and a beta of 0.55. The firm has a 50-day moving average of $24.86 and a 200-day moving average of $24.21. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.17.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the company posted $0.60 earnings per share. Pfizer’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.